<DOC>
	<DOCNO>NCT00868023</DOCNO>
	<brief_summary>Multinational , multicentre , randomise , double blind , double dummy , placebo active control , 5-way cross</brief_summary>
	<brief_title>Next DPI LABA , Multicentre , 5-way Cross-over , Adult Asthmatic Patients</brief_title>
	<detailed_description>To demonstrate non-inferiority term FEV1 AUC0-12h single dose CHF 1535 via NEXT DPI CHF 1535 via HFA-134a `` extrafine '' pMDI partly control adult asthmatic patient</detailed_description>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Patient 's write informed consent obtain prior studyrelated procedure . Outpatient male female age ≥ 18 year . Evidence `` partly control '' asthma 2 week screen visit Under previous inhaled corticosteroid ( ICS ) treatment screen visit Forced expiratory volume first second ( FEV1 ) ≥ 60 % ≤ 90 % predict normal value screen visit . A documented positive response reversibility test screen visit , define ΔFEV1 ≥ 12 % ≥ 200 mL baseline , 30 minute 400 μg salbutamol pMDI Patients free longacting beta2agonists ( LABAs ) treatment least 2 week screen visit . Patients free shortacting beta2agonists ( SABAs ) treatment least 6 hour screen visit . Nonsmokers exsmokers Pregnant lactate woman woman physiologically capable become pregnant UNLESS menopausal use effective acceptable method contraception . Significant seasonal variation asthma asthma occur episodic exposure allergen chemical sensitizer . History near fatal asthma ( e.g . brittle asthma , hospitalisation asthma exacerbation Intensive Care Unit ) within 1 year screening . Occurrence asthma exacerbation respiratory tract infection 4 week precede screen visit . Diagnosis Chronic Obstructive Pulmonary Disease ( COPD ) History cystic fibrosis , bronchiectasis alpha1 antitrypsin deficiency . Diagnosis restrictive lung disease . Patients treat oral parenteral corticosteroid previous 8 week ( 12 week parenteral depot corticosteroid ) screen visit . Intolerance contraindication treatment beta2agonists and/or inhaled corticosteroid . Allergy , sensitivity intolerance study drug excipients . Significant medical history and/or treatment cardiac , renal , neurological , hepatic , endocrine disease , laboratory abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>